Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

F. Cicchiello; F. Riva; M.E. Cazzaniga; F. Pedani; M. Nicolini; C. Butti; N. Liscia; C. Pogliani; G. Capri; M. Alù; A. Febbraro; L. Petrucelli; L. D'Onofrio; M. De Laurentiis; D. Pellegrini; L. Mentuccia; V. Cocciolone; E. Miraglio; E. Bajardi; M. Dester; E. Paternò; G. Guaitoli; I. Ferrarini; E. Gervasi; L. Licata; C. Benedetto; D. Andreis; E. Bordin; C. Ancona; L. Pizzuti; V. Fotia; R. Berardi; M. Airoldi; V. Arcangeli; S. Artale; F. Atzori; A. Ballerio; G.V. Bianchi; L. Blasi; S. Campidoglio; M. Ciccarese; M.C. Cursano; M. Piezzo; A. Fabi; L. Ferrari; A. Ferzi; C. Ficorella; A. Frassoldati; A. Fumagalli; O. Garrone; V. Gebbia; D. Generali; N. La Verde; M. Maur; A. Michelotti; G. Moretti; A. Musolino; R. Palumbo; M. Pistelli; M. Porpiglia; D. Sartori; C. Scavelli; A. Schirone; A. Turletti; M.R. Valerio; P. Vici; A. Zambelli; L. Clivio; V. Torri

doi:10.1016/j.breast.2017.06.043

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

F. Cicchiello, F. Riva, M.E. Cazzaniga, F. Pedani, M. Nicolini, C. Butti, N. Liscia, C. Pogliani, G. Capri, M. Alù, A. Febbraro, L. Petrucelli, L. D'Onofrio, M. De Laurentiis, D. Pellegrini, L. Mentuccia, V. Cocciolone, E. Miraglio, E. Bajardi, M. DesterE. Paternò, G. Guaitoli, I. Ferrarini, E. Gervasi, L. Licata, C. Benedetto, D. Andreis, E. Bordin, C. Ancona, L. Pizzuti, V. Fotia, R. Berardi, M. Airoldi, V. Arcangeli, S. Artale, F. Atzori, A. Ballerio, G.V. Bianchi, L. Blasi, S. Campidoglio, M. Ciccarese, M.C. Cursano, M. Piezzo, A. Fabi, L. Ferrari, A. Ferzi, C. Ficorella, A. Frassoldati, A. Fumagalli, O. Garrone, V. Gebbia, D. Generali, N. La Verde, M. Maur, A. Michelotti, G. Moretti, A. Musolino, R. Palumbo, M. Pistelli, M. Porpiglia, D. Sartori, C. Scavelli, A. Schirone, A. Turletti, M.R. Valerio, P. Vici, A. Zambelli, L. Clivio, V. Torri

Research output: Contribution to journal › Article › peer-review

Original language	Italian
Pages (from-to)	115-121
Number of pages	7
Journal	Breast
Volume	35
DOIs	https://doi.org/10.1016/j.breast.2017.06.043
Publication status	Published - 2017

Access to Document

10.1016/j.breast.2017.06.043

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023606118&doi=10.1016%2fj.breast.2017.06.043&partnerID=40&md5=4a230638ee168288dc59245c2017679e

Cite this

Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, M., Butti, C., Liscia, N., Pogliani, C., Capri, G., Alù, M., Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., ... Torri, V. (2017). Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. Breast, 35, 115-121. https://doi.org/10.1016/j.breast.2017.06.043

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. / Cicchiello, F.; Riva, F.; Cazzaniga, M.E. et al.

In: Breast, Vol. 35, 2017, p. 115-121.

Research output: Contribution to journal › Article › peer-review

Cicchiello, F, Riva, F, Cazzaniga, ME, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alù, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M , Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paternò, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, GV, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, MC, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, MR, Vici, P, Zambelli, A, Clivio, L & Torri, V 2017, 'Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study', Breast, vol. 35, pp. 115-121. https://doi.org/10.1016/j.breast.2017.06.043

@article{efa48f5568c144bdb564d1cf0f6a4735,

title = "Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study",

author = "F. Cicchiello and F. Riva and M.E. Cazzaniga and F. Pedani and M. Nicolini and C. Butti and N. Liscia and C. Pogliani and G. Capri and M. Al{\`u} and A. Febbraro and L. Petrucelli and L. D'Onofrio and {De Laurentiis}, M. and D. Pellegrini and L. Mentuccia and V. Cocciolone and E. Miraglio and E. Bajardi and M. Dester and E. Patern{\`o} and G. Guaitoli and I. Ferrarini and E. Gervasi and L. Licata and C. Benedetto and D. Andreis and E. Bordin and C. Ancona and L. Pizzuti and V. Fotia and R. Berardi and M. Airoldi and V. Arcangeli and S. Artale and F. Atzori and A. Ballerio and G.V. Bianchi and L. Blasi and S. Campidoglio and M. Ciccarese and M.C. Cursano and M. Piezzo and A. Fabi and L. Ferrari and A. Ferzi and C. Ficorella and A. Frassoldati and A. Fumagalli and O. Garrone and V. Gebbia and D. Generali and {La Verde}, N. and M. Maur and A. Michelotti and G. Moretti and A. Musolino and R. Palumbo and M. Pistelli and M. Porpiglia and D. Sartori and C. Scavelli and A. Schirone and A. Turletti and M.R. Valerio and P. Vici and A. Zambelli and L. Clivio and V. Torri",

note = "Export Date: 21 February 2018",

year = "2017",

doi = "10.1016/j.breast.2017.06.043",

language = "Italian",

volume = "35",

pages = "115--121",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

AU - Cicchiello, F.

AU - Riva, F.

AU - Cazzaniga, M.E.

AU - Pedani, F.

AU - Nicolini, M.

AU - Butti, C.

AU - Liscia, N.

AU - Pogliani, C.

AU - Capri, G.

AU - Alù, M.

AU - Febbraro, A.

AU - Petrucelli, L.

AU - D'Onofrio, L.

AU - De Laurentiis, M.

AU - Pellegrini, D.

AU - Mentuccia, L.

AU - Cocciolone, V.

AU - Miraglio, E.

AU - Bajardi, E.

AU - Dester, M.

AU - Paternò, E.

AU - Guaitoli, G.

AU - Ferrarini, I.

AU - Gervasi, E.

AU - Licata, L.

AU - Benedetto, C.

AU - Andreis, D.

AU - Bordin, E.

AU - Ancona, C.

AU - Pizzuti, L.

AU - Fotia, V.

AU - Berardi, R.

AU - Airoldi, M.

AU - Arcangeli, V.

AU - Artale, S.

AU - Atzori, F.

AU - Ballerio, A.

AU - Bianchi, G.V.

AU - Blasi, L.

AU - Campidoglio, S.

AU - Ciccarese, M.

AU - Cursano, M.C.

AU - Piezzo, M.

AU - Fabi, A.

AU - Ferrari, L.

AU - Ferzi, A.

AU - Ficorella, C.

AU - Frassoldati, A.

AU - Fumagalli, A.

AU - Garrone, O.

AU - Gebbia, V.

AU - Generali, D.

AU - La Verde, N.

AU - Maur, M.

AU - Michelotti, A.

AU - Moretti, G.

AU - Musolino, A.

AU - Palumbo, R.

AU - Pistelli, M.

AU - Porpiglia, M.

AU - Sartori, D.

AU - Scavelli, C.

AU - Schirone, A.

AU - Turletti, A.

AU - Valerio, M.R.

AU - Vici, P.

AU - Zambelli, A.

AU - Clivio, L.

AU - Torri, V.

N1 - Export Date: 21 February 2018

PY - 2017

Y1 - 2017

U2 - 10.1016/j.breast.2017.06.043

DO - 10.1016/j.breast.2017.06.043

M3 - Articolo

VL - 35

SP - 115

EP - 121

JO - Breast

JF - Breast

SN - 0960-9776

ER -